by François Briand | Oct 14, 2022 | 2022
Physiogenex will be presenting the effects of clinical benchmarks in its innovative obese NASH hamster model at the Discovery on Target in Boston, MA, USA, Oct 19th – Oct 20th, 2022. Meet our expert Dr François Briand, our Director of Research and Development during...
by François Briand | Sep 27, 2022 | 2022
Physiogenex will be presenting the cardiometabolic benefits of the GLP-1 receptor agonist semaglutide in its innovative obese NASH hamster model at the European Incretin Study Group 2022 meeting in Lausanne, Switzerland (Sept. 29th – Oct 1st). Meet Dr François...
by François Briand | Sep 15, 2022 | 2022
Physiogenex will be exhibiting at booth#D04 and presenting 2 oral abstracts at the EASD 2022 in Stockholm, Sweden Sept. 19-23. The first oral presentation, entitled “Time-restricted feeding and obeticholic acid/semaglutide drug combination have a different...
by François Briand | Aug 30, 2022 | 2022
Physiogenex will be presenting a new DIO mouse study at the 9th Aging Research and Drug Discovery (ARDD) Meeting in Copenhagen, Denmark, August 30th-September 2nd, 2022. The poster presentation, entitled “Metformin and time-restricted feeding combination...
by François Briand | Aug 25, 2022 | 2022
Physiogenex and its subsidiary company Cardiomedex will be presenting their original preclinical models during the Moderated ePosters session entitled “Pathomechanisms of heart failure with preserved ejection fraction” on August the 28th, 2022 2:15pm-3pm...
by François Briand | Jun 21, 2022 | 2022
Physiogenex will be exhibiting at booth#51 and presenting a new DIO-NASH mouse study (abstract#258) at the ILC-EASL in London, UK, on June 25th, 2022. The poster presentation (#SAT110), entitled “Weight loss with semaglutide treatment or time-restricted feeding...
